ClinicalTrials.gg
RecruitingNCT07422675Updated Nov 12, 2026

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

A Phase 1 interventional study of SER-252 (PEOZ-apomorphine) and enFuse in PARKINSON DISEASE (Disorder) and Advanced Parkinson's Disease, sponsored by Serina Therapeutics. Recruiting at 8 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Serina Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026First site in TaiwanSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
554th of 1,257
40 · median 36
Started
2026
with 83 others
Phase 1
175 of 1,650
32 open now
Primary completion
2027-01
later than 128 of 384 live
Registered
1,581st of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 554th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 84 that started in 2026, is one of 175 in phase 1, reaches primary completion later than 128 of the 384 other live ones, and was the 1,581st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.

Read the detailed description

Participants will be enrolled into five sequential groups. Each group will include eight participants, dosed in a 3:1 ratio (six receiving SER-252 and two receiving placebo). All participants will receive a single dose of study drug. Each successive group will receive a higher dose level of SER-252 than the previous group. Some participants will receive a subcutaneous injection of SER-252, while others will receive placebo.

Single ascending dose (SAD) cohorts will utilize a sentinel dosing approach, with subsequent dosing conducted in a staggered manner if ongoing safety and tolerability assessments allow. In each cohort, the first two participants (one receiving SER-252 and one receiving placebo) will be dosed separately ahead of the remaining participants. These sentinel participants will be observed and evaluated as described in the protocol before dosing proceeds for the rest of the cohort.

03

Conditions studied

  • PARKINSON DISEASE (Disorder)
  • Advanced Parkinson's Disease

Browse trials for

Keywords

  • advanced Parkinson's Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male participants 40-80 years of age, inclusive, at the time of screening
  2. Diagnosis of idiopathic Parkinson's disease consistent with UK Brain Bank and MDS Research Criteria; must include bradykinesia with sequence effect, motor asymmetry if no rest tremor, and a reliable, visible response to levodopa
  3. On a stable regimen of anti-Parkinsonian medication for at least 4 weeks prior to Screening; MAOBIs must be stable for at least 12 weeks prior to Screening
  4. Routine early-morning OFF, corroborated by investigator interview at Screening
  5. Presence of a total daily OFF time duration of ≥2 hours during the waking day based on participant self-assessment and Investigator's judgment
  6. *Hoehn and Yahr scale ≤ 3 in the ON state during screening (*part of the MDS- UPDRS Part III assessment)
  7. Levodopa administration at least 4 times daily (immediate or extended release) or three times daily (Rytary or Crexont)
  8. Ability to return to the clinic for blood sampling, clinical and laboratory assessment on scheduled days, based upon cohort
  9. ≥ 24
  10. Women of (WOCBP) who are sexually active with a male partner must use a reliable method of from the time of consent through at least 3 months after the last dose of study medication. Reliable methods of contraception include oral contraceptive or long-term injectable or implantable hormonal contraceptive, or intra-uterine devices when used in combination with male condoms, and must have a negative serum pregnancy test at Screening and negative urine pregnancy test at baseline. Males who are sexually active and whose partners are females of childbearing potential must agree to use male condoms from the time of consent through 3 months after administration of the last dose of study drug, and their partners must be willing to use a highly effective method of contraception from screening through 3 months after administration of the last dose of study drug.
  11. Willing and able to comply with all study activities and requirements, including safety follow-up
  12. Provide written
  13. Approved by a central Enrollment Authorization Committee (EAC)

Exclusion criteria

Exclusion criteria

  1. Diagnosis of secondary or atypical parkinsonism
  2. Any previous procedure or therapy designed to provide continuous levodopa or stimulation of dopaminergic tone (i.e., Duopa, apomorphine), surgery for PD (i.e., DBS), or anticipation of these during the study
  3. History of exclusively diphasic, OFF state, myoclonic or dystonic dyskinesias without peak-dose choreiform dyskinesia
  4. Clinically debilitating motor complications as determined by the principal investigator or delegate (severe, disabling dyskinesias or severe OFF)
  5. Participant inability to differentiate motor states (OFF/ON/ON with mild/moderate/severe dyskinesias) after training
  6. orthostatic hypotension (consistently symptomatic or requires medication)
  7. Clinically significant hallucinations requiring antipsychotic use
  8. Clinically significant medical, surgical, psychiatric, or laboratory abnormalities that in the judgment of the principal investigator or delegate would preclude adequate participation or completion of the study
  9. Clinically significant abnormalities at Screening
  10. Prolonged Fridericia- (QTcF) interval on ECG at Screening (defined as a QTcF interval of >450 msec for males and 470 for females)
  11. Clinically significant heart disease within 2 years of Screening, defined as follows:

    A. Significant cardiac event within 12 weeks prior to Screening (e.g., admission for myocardial infarction, unstable angina, or decompensated heart failure), angina pectoris or episode of congestive heart failure with symptoms > grade 2 classification, or presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia B. History of complex arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia) that was symptomatic or required treatment ( grade 3) C. Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia D. Symptomatic bradycardia, sick sinus syndrome or atrioventricular block greater than first degree in the absence of a pacemaker E. Unexplained syncope F. Brugada syndrome G. Hypertrophic cardiomyopathy

  12. Active major depressive disorder or history of clinically significant impulse control disorder, in the opinion of the Principal Investigator or delegate, or EAC.

    Note: Participants receiving treatment for depression with antidepressants may be enrolled if they have been on a stable daily dose of the antidepressant for at least 8 weeks prior to Screening.

  13. Has active suicidal ideation within one year prior to Screening as determined by the C-SSRS (answer of "yes" on questions 4 or 5) or attempted suicide within the last 5 years
  14. Has been diagnosed with or history of a substance-related disorder (excluding nicotine and caffeine), including alcohol-related disorder by criteria, during the 12 months prior to Screening
  15. Tests positive at Screening for drugs of abuse (amphetamines (AMP), barbiturates (BAR), benzodiazepines (BZO), cocaine (COC), opiates (OPI), methamphetamines (MET), methadone (MTD), Phencyclidine (PCP), tetrahydrocannabinol (THC), tricyclic antidepressants (TCA)) Note: does not exclude patients on physician-prescribed medications.
  16. Has or AST levels greater than 2.5 times the or > 2.0 mg/dL, or > 34.2 µmol/L
  17. Significant renal impairment as determined by , using method, less than or equal to 55 ml/min or serum creatinine >2.0 mg/dL or >177 µmol/L
  18. Has a positive test result for , antibody, or infection at Screening
  19. Currently lactating or pregnant or planning to become pregnant during the study.
  20. Previous intolerance of apomorphine
  21. Currently participating in or has participated in another study within the last 30 days or 5 half-lives, or 90 days for biologics
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    SER-252 (PEOZ-apomorphine)

    SER-252 (PEOZ-apomorphine) Single subcutaneous dose delivered by enFuse® on body device; weight-based apomorphine equivalents/kg by cohort: 0.48, 0.60, 0.75, 0.90, 1.0 mg-eq/kg. SER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% trehalose to maintain final pH and isotonicity in the reconstituted product.

    Drug: SER-252 (PEOZ-apomorphine) · Device: enFuse

  • Placebo comparator
    Diluent Product

    The SER-252 Diluent Product, 12 ml size will be used as the placebo formulation. The appearance of the diluent product is clear and colorless. Matching subcutaneous administration by the same device.

    Device: enFuse

Interventions

  • DrugSER-252 (PEOZ-apomorphine)

    SER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% trehalose to maintain final pH and isotonicity in the reconstituted product.

  • DeviceenFuse

    The enFuse® device is a sterile, non-pyrogenic, user-filled, single-use, fixed-dose subcutaneous dose delivery system.

06

What researchers measure

Primary outcomes

  1. Incidence and Temporal Profile of Treatment-Emergent Adverse Events (TEAEs)

    Proportion of participants with TEAEs (new onset or worsening) and temporal profile post-dose; TEAEs summarized by type/nature, severity/intensity, seriousness, and relationship to study treatment per protocol.

    Time frame: From first dose through Day 21 (7 days after the Day 14 end-of-participation visit).

  2. Incidence of Moderate or Severe TEAEs Related to Study Intervention

    Proportion of participants experiencing moderate or severe TEAEs related to study intervention (including possibly and probably related).

    Time frame: From first dose through Day 21 (7 days after the Day 14 end-of-participation visit).

  3. Incidence of Serious Adverse Events (SAEs), including suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)

    Proportion of participants with SAEs (ICH-GCP), including suicidality identified via C-SSRS

    Time frame: From first dose through Day 44 (30 days after the Day 14 end-of-participation visit).

  4. Change from Baseline in Vital Signs

    Mean change from baseline in systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature.

    Time frame: Baseline to Day 8 (with Day 14 follow-up vitals also collected)

  5. Area under the concentration-time curve (AUC0-24, AUC0-96, AUC0-∞)

    AUC from time zero to infinity hours post-dose, calculated using noncompartmental methods (ng·h/mL)

    Time frame: Day 1 through Day 8 (0-168 hours post-dose)

  6. Change from Baseline in Corrected QT Interval (QTcF)

    Mean change from baseline in Fridericia-corrected QT interval (QTcF) from 12-lead ECGs. (millisecond (ms))

    Time frame: Baseline to Day 8 (with Day 14 safety follow-up ECGs).

  7. Time to Maximum Plasma Concentration (Tmax)

    Observed time to reach Cmax (first occurrence), based on the protocol-defined sampling schedule. (hours)

    Time frame: Day 1 through Day 8 (0-168 hours post-dose).

  8. Change from Baseline in Clinical Laboratory Parameters

    Mean change from baseline in hematology and serum chemistry panels.

    Time frame: Baseline to Day 8 (laboratories at safety follow-up only if needed to follow up abnormalities).

  9. Fluctuation Index (FI)

    FI calculated as (Cmax - Cmin) / Cavg over 0-168 hours.

    Time frame: Day 1 through Day 8 (0-168 hours)

  10. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)

    Incidence and severity of impulsive-compulsive behaviors assessed by QUIP-RS. The QUIP-RS total score ranges 0-112, with higher scores indicating more severe symptoms.

    Time frame: Screening/Day -1 and Day 8.

  11. Trough Concentration (Ctrough)

    Observed plasma concentrations at nominal trough timepoints: 24, 48, 72, 96, 120, 144, and 168 hours post-dose. (ng/mL)

    Time frame: Days 2-8 (24-168 hours post-dose).

  12. Coefficient of Variation (CV%) for Exposure

    Between-participant variability in key PK parameters (e.g., Cmax, AUC), calculated as 100 × (SD / mean).

    Time frame: Day 1 through Day 8 (0-168 hours).

  13. Distributional Half-Life (h)

    Distributional half-life estimated from the distribution phase of the concentration-time profile, when model assumptions permit. (hours)

    Time frame: Day 1 through Day 8

  14. Maximum Plasma Concentration (Cmax)

    Cmax of SER-252-derived apomorphine following a single subcutaneous dose, derived from plasma concentrations collected at: pre-dose (0), 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 hours on Day 1; and 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, and 168 hours post-dose.(ng/mL)

    Time frame: Day 1 through Day 8 (0-168 hours post-dose)

Other outcomes

  1. Exploratory Efficacy Endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II

    MDS-UPDRS Part II Change from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score. The MDS-UPDRS Part II assesses motor aspects of daily living on a scale from 0 to 52, with higher scores indicating greater impairment.

    Time frame: Change from Baseline at Day 8

  2. Exploratory Efficacy Endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III - Change from Baseline at 4 Hours

    Change from baseline in the MDS-UPDRS Part III (motor examination) total score at 4 hours post-dose. The MDS-UPDRS Part III ranges from 0 to 132, with higher scores indicating greater motor impairment. Time Frame: Baseline to 4 hours post-dose.

    Time frame: Baseline to 4 hours post dose

  3. Exploratory Efficacy Endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III - Maximum Daily Change from Baseline

    Maximum (most extreme) change from baseline in MDS-UPDRS Part III total score observed across the following post-dose timepoints: 1, 2, 3, 4, 6, 9, and 12 hours. Scale range: 0-132, higher scores = worse.

    Time frame: Baseline to 12 hours post-dose

  4. Exploratory Efficacy Endpoint: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III - Area Under the Curve (AUC)

    AUC of change from baseline in MDS-UPDRS Part III total score over the following timepoints: baseline and 1, 2, 3, 4, 6, 9, and 12 hours post-dose. Positive AUC values indicate net worsening; negative values indicate net improvement over time. Scale range: 0-132, higher scores = worse. Time Frame: Baseline to 12 hours post-dose.

    Time frame: Baseline to 12 hours post-dose

07

Study locations

7 of 8 sites recruiting
  • Rocky Mountain Clinical Research
    Englewood, Colorado 80113, United States
    Recruiting
    • Jessica Study Coordinator · Contactj.crall@cenexel.com · 303-357-5456
    • Meagan Salinas, MD · Principal investigator
  • Velocity Clinical Research
    Hallandale, Florida 33009, United States
    Recruiting
  • K2 Medical Research LLC
    Maitland, Florida 32751, United States
    Recruiting
    • Sheila Baez-Torres, MD · Principal investigator
  • Quest Research Institute
    Farmington Hills, Michigan 28555, United States
    Recruiting
  • Inland Northwest Research
    Spokane, Washington 99202, United States
    Recruiting
  • CMAX
    Adelaide, South Australia 5000, Australia
    Recruiting
  • Monash
    Melbourne, Victoria 3170, Australia
    Completed

    Not enrolling at this site.

  • Shaung Ho Hospital - Clinical Research Center
    Taipei, Taiwan
    Recruiting
    • Chaur-Jong Hu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 11 months is above that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Feb 20, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added — first site in Taiwan. 2 sites changed recruiting status (1 now recruiting, 1 now completed)
Show 2 sites
  • Rocky Mountain Clinical Research · Englewood, United StatesNot yet recruiting→Recruiting
  • Monash · Melbourne, AustraliaRecruiting→Completed
Show 2 added (1 United States, 1 Taiwan)
  • Inland Northwest Research · Spokane, United States
  • Shaung Ho Hospital - Clinical Research Center · Taipei, Taiwan
Nov 12, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Rocky Mountain Clinical Research · Englewood, United StatesContact H•••@questri.com · •••8940→j•••@cenexel.com · •••5456
  • Monash · Melbourne, AustraliaContact removed r•••@monashhouse.com.au · •••0700Contact removed (no phone or email listed)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    2 sites added — first site in Taiwan. 2 sites changed recruiting status (1 now recruiting, 1 now completed)
    Show 2 sites
    • Rocky Mountain Clinical Research · Englewood, United StatesNot yet recruiting→Recruiting
    • Monash · Melbourne, AustraliaRecruiting→Completed
    Show 2 added (1 United States, 1 Taiwan)
    • Inland Northwest Research · Spokane, United States
    • Shaung Ho Hospital - Clinical Research Center · Taipei, Taiwan
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Rocky Mountain Clinical Research · Englewood, United StatesContact H•••@questri.com · •••8940→j•••@cenexel.com · •••5456
    • Monash · Melbourne, AustraliaContact removed r•••@monashhouse.com.au · •••0700Contact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07422675
Lead sponsor
Serina Therapeutics
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 1, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Randall Moreadith, MD, PhD
Contact
rmoreadith@serinatherapeutics.com
(256) 783-7649

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion